BioCentury
ARTICLE | Finance

With $76M series B, BlackThorn looks to build out neurobehavioral platform

How BlackThorn rebounded from a January clinical setback to raise $76 million to develop its targeted therapies for neurobehavioral disorders

June 13, 2019 12:31 PM UTC

BlackThorn has amassed a $76 million series B round from investors who are banking on the potential of its PathFinder platform to circumvent the issue of patient heterogeneity in neurobehavioral disorders.

New investors Polaris Partners, Premier Partners, Scripps Research and Vertex Ventures HC participated in the round alongside existing investors Alexandria Venture Investments, Altitude Life Science Ventures, Arch Venture Partners, Biomatics Capital, GV, Johnson & Johnson Innovation -- JJDC Inc. and Mercury Fund. ...

BCIQ Company Profiles

BlackThorn Therapeutics Inc.